Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

DOI Web Site Web Site 30 Citations 74 References
  • R Nakashima
    Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan
  • Y Hosono
    Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan
  • T Mimori
    Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan

Description

<jats:p>Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 ( MDA5) antibodies are closely associated with interstitial lung disease in polymyositis and dermatomyositis. Anti-ARS-positive patients develop common clinical characteristics termed anti-synthetase syndrome and share a common clinical course, in which they respond well to initial treatment with glucocorticoids but in which disease tends to recur when glucocorticoids are tapered. Anti- MDA5 antibody is associated with rapidly progressive interstitial lung disease and poor prognosis, particularly in Asia. Therefore, intensive immunosuppressive therapy is required for anti- MDA5-positive patients from the early phase of the disease. New enzyme-linked immunosorbent assays to detect anti-ARS and anti- MDA5 antibodies have recently been established and are suggested to be efficient and useful. These assays are expected to be widely applied in daily practice.</jats:p>

Journal

  • Lupus

    Lupus 25 (8), 925-933, 2016-05-31

    SAGE Publications

Citations (30)*help

See more

References(74)*help

See more

Related Projects

See more

Report a problem

Back to top